BACKGROUND: Small tumor diagnostic tools including ultrasound-guided fine needle aspiration (FNA) and computed tomography (CT) could be causing rising and racially/ethnically different thyroid cancer incidence rates due to variable overdiagnosis of indolent tumors. Papillary tumors and <40 mm tumors are most likely to be overdiagnosed as indolent tumors by FNA and CT. METHODS: Age-adjusted incidence rates (AAIRs) for the years 2007-2014 were calculated for race/ethnicity (white, Hispanic, Asian, African American, Native American) by patient/tumor characteristics for microscopically confirmed malignant thyroid cancer cases in the Surveillance, Epidemiology, and End Results Program 18 database (SEER 18; N 5 93,607). Multivariate analysis determined cancer patients' odds ratios of diagnosis with papillary thyroid carcinoma (vs other histologies) and tumors <40 mm (vs 40 mm). RESULTS: For both males and females, there were statistically significant differences in incidence rates between race/ethnicity, with whites having the highest AAIRs and African Americans the lowest AAIRs. Among thyroid cancer patients, tumor size and histology differed significantly by race and insurance coverage after controlling for age, sex, stage, and tumor sequence. Non-whites with thyroid cancer (vs whites) were less associated with small tumors (odds ratio [OR], 0.51-0.79; P < .0001). Medicaid and uninsured patients with thyroid cancer were less associated with tumors <40 mm (OR, 0.55-0.71; 95% confidence interval [CI], 0.49-0.76) and papillary carcinoma (OR, 0.86; 95% CI,. CONCLUSION: The diagnosis of small tumors is occurring at greater rates in whites (vs non-whites) and insured (vs Medicaid and uninsured) patients; consequently, these groups may be vulnerable to unnecessary tests and treatments or potentially aided by early detection. Guidelines that define postdetection interventions may be needed to limit the overtreatment of indolent and small papillary carcinomas. Cancer 2018;124:1483-91.
INTRODUCTION
Within the United States, thyroid cancer is the eighth most common cancer, with an estimated 56,870 new diagnoses in 2017 and an estimated prevalence of 726,646 confirmed persons living with thyroid cancer in 2014. 1, 2 Although thyroid cancer makes up just 3.4% of new cancers diagnosed, incidence rates have increased dramatically over the last 30 years in all age groups, making thyroid cancer rates an important health concern. 3, 4 Epidemiologists believe this increase will lead to thyroid cancer becoming the fourth most prevalent cancer in the United States by 2030. 3, 5 The etiology of increasing incidence in the United States is unknown. [6] [7] [8] Worldwide risk factors for thyroid cancer include inadequate and excessive dietary iodine, thyroid problems (eg, goiter, benign nodules, adenomas), and radiation exposure. 3, [7] [8] [9] Researchers have attributed the rising rates of thyroid cancer in the United States to the improvement of diagnostic techniques, specifically ultrasound (US)-guided fine needle aspiration (FNA) and computed tomography (CT). 3, 10 The introduction of US-guided FNA into the United States health care system in the 1990s enabled the detection of tumors not easily discovered by palpation. 3, 10 According to the American Joint Committee on Cancer (AJCC) 8th edition, stage I tumors are <40 mm and have no metastasis outside of the thyroid; thus, they should be the most difficult to detect by palpation alone. [11] [12] [13] Stage I tumors (vs stages II-IV) and papillary carcinoma (vs medullary, follicular, anaplastic) are currently the 2 categories of thyroid cancer that are most overdiagnosed by US-guided FNA.
14 Due to potential unequal access to US-guided FNA, overdiagnosis (ie, detecting tumors that have not produced clinical symptoms and may never become a health concern) may vary between populations in that some populations have greater access to preventive health care and therefore greater access to diagnostic techniques for early detection.
The diagnosis of small tumors through greater access to technology could be beneficial in some cases because it may detect early cancers before metastasis and local expansion. On the other hand, overdiagnosis with this technology could be harmful, because it may lead to unnecessary biopsy, surgery, radiation, and interventions, all of which have associated health risks. Although many researchers have suggested overdiagnosis is the cause of rising thyroid cancer incidence rates in the United States, epidemiologists have yet to rule out an actual increase in incidence rates, and furthermore have suggested alternate explanations for the rising rates, including biological or genetic factors, environmental exposure, comorbidity, and lack of treatment adherence. 3, 4, 9, [15] [16] [17] [18] [19] [20] Thyroid cancer incidence varies by race/ethnicity. 18, 20 According to the National Cancer Institute's Surveillance, Epidemiology, and End Results 18 Program database (SEER 18), from 2000-2014, whites had the highest estimated thyroid cancer incidence rate, followed by Hispanics, Asians, Native Americans, and African Americans. 21 In contrast, many other cancers (eg, colorectal, gastric, head and neck, lung, and prostate) have racial/ ethnic disparities that show the highest incidence rates in African Americans. 18, 22 Descriptive reports have suggested that these racial/ethnic differences could have arisen from dissimilar access to US-guided FNA and CT, a manifestation of variances in socio-economic status and insurance coverage. 10, [23] [24] [25] [26] If this is true, age-adjusted incidence rates (AAIRs) and odds ratios (ORs) would vary by race/ethnicity primarily in stage I papillary carcinomas that are <40 mm in size. The purpose of this study was to investigate recent AAIRs of thyroid cancer by race/ethnicity across tumor and patient characteristics to determine their potential relationship to diagnostic technology and to investigate the association between race/ethnicity and tumor size and histology among patients with thyroid cancer.
MATERIALS AND METHODS
Using SEER 18 data, AAIRs were calculated for each racial/ethnic group from 2007 to 2014. 27 Race/ethnicity was categorized into 5 groups: white Hispanic (hereafter referred to as Hispanic), white non-Hispanic (hereafter referred to as white), black non-Hispanic (hereafter referred to as African American), Asian and Pacific Islander (hereafter referred to as Asian), and Alaskan Native/American Indian (hereafter referred to as Native American Incidence rates were also calculated for tumor sequence number at diagnosis, where thyroid cancer was either the first cancer diagnosed or was the second or otherwise (hereafter referred to as second and higher) diagnosed.
The county-level variables of poverty and education were also included in our multivariate analysis as a proxy for socioeconomic variables. The poverty variable was based on the county in which subjects resided at the time of their thyroid cancer diagnosis, and each county was categorized as having <20% or 20% of the population living below 200% of the poverty level based on the Census American Community Survey 5-year files for 2010-2014. Similarly, the education variable was based on county, and categorized each county as having <10% versus 10% of the population having less than a high school education.
Population-based AAIRs and 95% confidence intervals were calculated for the 8-year period of 2007-2014 using the 2000 United States standard population reported per 100,000 person-years. Data and software used to obtain these measures for patient, tumor, and socioeconomic variables were provided through SEER*-Stat version 8.3.4. 27 Thyroid cancer AAIRs were only reported if at least 25 patients existed within a category.
Multivariate logistic regression analysis via SAS (version 9.4, SAS Institute, Cary, NC) was used to calculate ORs to determine the independent factors associated with tumor size and histology among patients with thyroid cancer. Model 1 compared the factors associated with diagnosis of papillary carcinoma, the least lethal and Original Article smallest carcinoma that saw improved diagnosis with USguided FNA, versus diagnosis with follicular, medullary, and anaplastic carcinomas. [29] [30] [31] [32] Model 2 compared the factors associated with diagnosis of tumors <40 mm, the size range whose diagnosis is aided by US-guided FNA and is within the stage I cancer range in the AJCC 8th edition, compared with tumors 40 mm. 13, 17 Results examined the associations between race/ethnicity and tumor size/histology of thyroid cancer patients while adjusting for age, sex, insurance status, tumor sequence at diagnosis, poverty level of county, and education level of county. These models also included bivariate interaction terms. Missing data and groupings of <25 patients were excluded from the multivariate analysis. Statistical significance was set at P < .05. The c-statistic was used to select the models presented herein.
The University of Iowa Human Subjects' Office determined this study did not meet their criteria for human subjects' research because it was limited to the analysis of deidentified data.
RESULTS
Between 2007 and 2014, there were 93,607 microscopically confirmed diagnoses of malignant thyroid cancer in the United States, with the majority involving whites, followed by Hispanics, Asians, African Americans, and Native Americans (68%, 15%, 10%, 7%, and 1%, respectively) ( Table 1 ). Race/ethnicity was statistically different over time in chi-square tests producing P values <.0001. The AAIRs per 100,000 person-years increased for all races over the 8-year period (Table 2) . Whites (15.1) had the highest incidence rate, followed by Asians (13.6), Hispanics (12.2), Native Americans (10.1), and African Americans (8.4).
For both males and females, there were statistically significant differences in incidence rates between race/ethnicity, with whites having the highest AAIRs and African Americans the lowest AAIRs ( Table 2 ). The rate ratio of females to males was 3:1 to 4:1 in each race/ethnicity group. The female and male AAIRs decreased from whites (22.4; 7.9), Asians (19.8; 6.4), Hispanics (19.3; 5.1), Native Americans (15.2; 4.5), to African Americans (12.5; 3.6), respectively.
For those diagnosed from the ages of 15-54 years, there were statistically significant differences in incidence rates decreasing in order from white to Asian, Hispanic, Native American, and African American. For those diagnosed from 55 to 84 years old, African Americans maintained significantly lower rates than all other race/ ethnicity groups. For those aged 85 years, there were no statistically significant differences in incidence rates between races/ethnicities.
AAIRs varied significantly between race/ethnicity groups for histology (papillary, follicular, medullary). Papillary carcinoma incidence rates among all races/ethnicities varied far more widely by race/ethnicity compared with all other histologies, with whites having the highest AAIRs (13.4), and African Americans having the lowest AAIRs (6.8) ( Table 2) . With regard to follicular and medullary carcinoma, whites had statistically higher AAIRs than Hispanics, Asians, or African Americans.
AAIRs varied significantly by tumor size at diagnosis (0-39 mm) and tumor stage at diagnosis (I-IV) ( Table 2 ). Whites had a higher incidence rate than all other races when looking at tumors <20 mm. For tumors 20-39 mm, whites had a significantly higher incidence than African Americans. For tumors 40 mm, there were no statistically significant differences between whites and the other races/ethnicities.
Stage I AAIRs decreased from whites (14.9) to Asians (12.3), Native Americans (10.5), Hispanics (10.3), to African Americans (6.5). Whereas whites had a significantly higher incidence for stage II, Asians and Hispanics had significantly higher incidence rates for stages III and IV.
Incidence rates varied significantly by race/ethnicity for insured and Medicaid patients. AAIRs (white, African American, Asian, Hispanic) for insured patients were over 6-fold greater than AAIRs for patients with Medicaid or no insurance. Among insured persons, whites had significantly greater AAIRs of thyroid cancer than other race/ ethnicity groups (Fig. 1) . Conversely, white Medicaid patients had significantly lower AAIRs than all other race/ ethnicity Medicaid patients. Hispanics had the greatest AAIRs among those uninsured; otherwise, there was no significant difference between the AAIRs of the other races/ethnicities, including whites and African Americans, among those uninsured.
AAIRs of thyroid cancer as a first cancer decreased over an almost 2-fold range across race/ethnicity, with whites having the highest AAIRs (13.1) and African Americans having the lowest AAIRs (7.3). As a second cancer, the incidence rates of thyroid cancer were also greatest in whites (2.0) and lowest in African Americans (1.1).
The multivariate analysis of patients with thyroid cancer (Table 3) showed race/ethnicity groups vary (P < .0001) in their odds of being diagnosed with papillary carcinoma (compared with medullary, anaplastic, and follicular) and small tumors (<40 mm) (vs large tumors). Compared with whites, Asians and Hispanics had 40% and 37% greater odds, respectively, of being diagnosed with papillary thyroid carcinoma, whereas African Americans had 28% lower odds. Non-whites were a quarter to half less likely to have smaller tumors (<40 mm) compared with whites. In addition to race/ethnicity, other variables including sex, age at diagnosis, insurance status, histology, and tumor sequence were significantly associated with tumor size (Table 3) 
DISCUSSION
Our analysis updates and quantifies previous descriptive studies of thyroid cancer incidence trends in the United States, particularly regarding our comparison of thyroid cancer incidence rates by race/ethnicity in the United States across personal and tumor characteristics from 2007 to 2014 in SEER 18 , and our multivariate analysis of thyroid cancer patients diagnosed with papillary carcinoma (vs other histologies) or with small tumors (<40 mm) (vs large tumors) from 2007 to 2014. Previous studies have suggested that racial/ethnic differences in AAIRs and increasing trends of AAIRs were due to dissimilarities in access to technology and resultant overdiagnosis of subclinical thyroid cancers. 3, 10, 15, 23 AAIRs for the period 2007-2014 showed thyroid cancer incidence trends similar to those of past studies, with whites having the highest incidence and African Americans the lowest. Consistent with previous studies, we conclude the differences in AAIRs could be due to dissimilar access to technology, especially because insurance AAIRs differed greatly between whites and African Americans. The AAIRs of thyroid cancer in insured patients were highest in whites and lowest in African Americans, but AAIRs were greater in African American Medicaid patients (vs white Medicaid patients), and there was no difference in incidence in uninsured patients.
Adding to past studies, our multivariate analysis of thyroid cancer patients revealed that whites (vs nonwhites) with thyroid cancer have greater odds of having tumors <40 mm. This finding is likely due to variability between races in the diagnosis of indolent disease (tumors that have not begun to produce symptoms or create clinical apparent disease) with the aid of new technology, a likely result of variability between races in their access to this technology. Our findings could mean that whites with thyroid cancer are more likely to be subjected to unnecessary tests, biopsies, and medical interventions because they have higher odds (than other cancer patients) of being diagnosed when their tumors are small and possibly indolent. However, it is also possible that with greater diagnosis of small tumors, white thyroid cancer patients (vs non-white) could potentially be having clinically significant tumors advantageously diagnosed before they metastasize or grow larger.
Given that nonpapillary tumors are generally more aggressive compared with papillary tumors, it is unexpected that our regression analysis of thyroid cancer patients revealed that African Americans have higher odds of nonpapillary thyroid cancer compared with whites, but our analysis of the general population revealed that African Americans do not have higher AAIRs for more advanced stage cancer (II-IV) compared with whites. On the other hand, Asians and Hispanics with thyroid cancer have higher odds of having papillary thyroid carcinoma compared with whites, yet have higher AAIRs for more advanced stage cancer compared with whites. 13, 21 Although it is encouraging that African Americans do not have higher rates of stage III/IV thyroid cancer compared with whites, especially given their higher odds of having nonpapillary thyroid cancers, it is concerning that Asians and Hispanics are being diagnosed with higher rates of stage II/IV thyroid cancer given their higher odds of papillary carcinoma. This finding warrants further investigation.
All non-whites with thyroid cancer have lower odds of tumors <40 mm compared with whites after controlling for other tumor and patient factors. In addition, the differences between AAIRs by tumor size became substantially more comparable between races once tumors were 40 mm. Thus, it therefore appears that compared with non-whites, and especially African Americans, whites have greater exposure to the health care system and USguided FNA when tumors are small and likely All bold face ORs are statistically significant using a P < .05.
nonpalpable, but once tumors grow to 40 mm and are likely palpable, the various races/ethnicities seek care more similarly to one another. Our multivariate analysis of patients with thyroid cancer found that insured patients (vs Medicaid patients) were 29% more associated with small tumors and 14% more associated with papillary carcinoma after accounting for other patient factors. Insured patients (vs uninsured) were 45% more associated with small tumors. Within each race, insured patients had 5-to 13-fold greater AAIRs than those with Medicaid, and 15-to 40-fold greater AAIRs than uninsured patients. Among insured patients, whites had the highest AAIRs; conversely, in the Medicaid and uninsured categories, whites had the lowest AAIRs (Fig. 1) . Of notice, a study conducted within the United States Department of Defense on members of the United States Armed Forces and their dependents, who all had similar benefits and access to health care, found no differences in subclinical detection between whites and African Americans. 26 Furthermore, Hispanics without insurance had AAIRs 2-3 times greater than those of whites without insurance, whereas insured Hispanics had incidence rates 35% lower than insured whites. These findings suggest that race/ethnicity and insurance status together affect the AAIRs of thyroid cancer.
Our multivariate analysis of thyroid cancer patients also revealed that women with thyroid cancer and second cancer patients were more likely to be diagnosed with small tumors (<40 mm) compared with men. The 2013 Kaiser survey suggested that women visit health care providers more frequently and receive general checkups more often than males, so it is possible that at least part of the sex difference in tumor size is related to health care system use. 33 Our analysis of the general population showed that women had much higher AAIRs of thyroid cancer compared with men. Further investigation is warranted to better understand the extent to which higher incidence among females is related to health care use versus biological, autoimmune, hormonal, or genetic factors. 15 Finally, our multivariate analysis of thyroid cancer patients showed that second cancer patients were more likely to be diagnosed with small tumors (<40 mm). It is possible that cancer survivors and those with past tumor diagnoses could be accessing US-guided FNA and other diagnostic examinations in association with more frequent follow-up surveillance.
A limitation to our study is that SEER is retrospective and has a limited number of reportable variables; this did not allow us to examine differences in known thyroid cancer risk factors between race/ethnicity, such as radiation exposure. Furthermore, errors in reporting race and ethnicity in medical records and death certificates may underestimate incidence rates in non-white populations. Race and ethnicity categories are not homogenous; differences may exist in subgroups within each race/ethnicity and thus, overall race/ethnicity trends may not be representative of all subsets. Moreover, some categories have low patient representation, particularly the Native American category, which may lead to imprecise rates. Increased analysis of Native American thyroid cancer AAIRs is needed to gain a more complete understanding of their risk. Finally, a limitation of the study is that we had to use county level education and poverty variables.
Our study has a number of strengths and novel components. First, this analysis included more recent SEER data including insurance information that was not available prior to 2006. We are therefore among the first to examine the interplay between thyroid cancer incidence, race/ethnicity and insurance coverage using populationbased SEER data. We are also among the first to evaluate population-based incidence trends applying the new AJCC 8th edition tumor stage I size limits to our analysis, which allowed us to newly comment on incidence under these new guidelines. The large sample size of SEER 18 allowed for more precise risk estimates than previous studies that used SEER 9 and 12; this allowed us to include several potential covariates in our multivariate analysis.
Our analysis of the most recent years of data available in the SEER database indicates that white race and private insurance coverage are significantly associated with smaller tumors and papillary carcinoma. This suggests that greater access to US-guided FNA in some populations is a driver of race/ethnicity differences in the incidence of thyroid cancer and may lead to increased diagnosis of thyroid cancer. Diagnosis of small tumors could leave those with greater access to US-guided FNA more vulnerable to unnecessary tests and treatments, or potentially could aid these populations with early detection before metastasis or further tumor growth. Guidelines may be needed that define postdetection interventions to limit overtreatment of indolent, smallsized, papillary carcinomas. Ongoing clinical trials evaluating active surveillance of small papillary thyroid cancers can hopefully inform these guidelines. 24, 34, 35 In addition, educating patients about thyroid cancer overdiagnosis and the risks associated with potential overtreatment of thyroid cancer may allow patients to be more engaged in shared decision making so they can help determine their best course of action. 14, 34, 35 
